STOCK TITAN

Coherus Oncology, Inc. (CHRS) Revenue by Year

CHRS

Coherus Oncology, Inc. generated $42.2M in revenue in fiscal year 2025. This represents an increase of 59.8% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $50.9M in revenue. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Coherus Oncology, Inc. has filed alongside them.

FY2025 annual
Revenue $42.2M
YoY +59.8%
5Y CAGR -38.4%
10Y CAGR +3.5%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

CHRS Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY238-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-K
Revenue$50.9M$42.2M+59.8%$26.4M+2066.6%$1.2M-99.4%$211.0M-35.4%$326.6M-31.4%$475.8M+33.6%$356.1M$0-100.0%$1.6M-99.2%$190.1M+532.8%$30.0M-3.4%$31.1M+1030.7%$2.8M+44.9%$1.9M

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

CHRS Revenue by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'238-KQ3'2310-Q
Revenue$14.3M+39.5%$12.3M+62.0%$12.7M+64.9%$11.6M+91.2%$10.3M-0.4%$7.6M+229.2%$7.7M$6.1M-91.9%$10.3M-82.5%$2.3M-92.9%N/A$74.6M+64.2%

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Coherus Oncology, Inc. financials

Frequently Asked Questions

What was Coherus Oncology, Inc.'s revenue in fiscal year 2025?

Coherus Oncology, Inc. generated $42.2M in revenue in fiscal year 2025.

How fast is Coherus Oncology, Inc.'s revenue growing?

Coherus Oncology, Inc. (CHRS) revenue rose by 59.8% year over year, from $26.4M to $42.2M in fiscal year 2025.

What is Coherus Oncology, Inc.'s revenue over the last twelve months?

Coherus Oncology, Inc. (CHRS) reported $50.9M in revenue over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 14 fiscal years this page covers, Coherus Oncology, Inc. (CHRS) revenue went from $1.9M in fiscal year 2012 to $42.2M in fiscal year 2025.

Coherus Oncology, Inc. (CHRS) reported $14.3M in revenue in Q2 2026. This represents an increase of 39.5% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Coherus Oncology, Inc. (CHRS) reported on that line in every period on record.